**SUPPLEMENTARY TABLE AND FIGURE**

**SUPPLEMENTARY TABLE S1.** Treatment Exposure by Treatment Arm in the Overall Treated Population and in Chemorefractory and Chemosensitive Subgroups.

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Overall population** | **Chemorefractory subgroup** | **Chemosensitive subgroup** |
| **Cabazitaxel(n = 89)** | **Topotecan(n = 88)** | **Cabazitaxel****(n = 45)** | **Topotecan****(n = 43)** | **Cabazitaxel****(n = 44)** | **Topotecan****(n = 45)** |
| **Median number of treatment cycles (range)** | 2.0(1–20) | 4.0(1–11) | 2.0(1–20) | 3.0(1–8) | 2.5(1–8) | 4.0(1–11) |
| **Median relative dose intensity,\*% (range)** | 98.9(61.1–103.0) | 91.8(57.6–104.8) | 98.9(72.5–101.7) | 93.2(59.2–104.8) | 98.6(61.1–103.0) | 86.8(57.6–101.6) |
| **Treatment discontinuation, n (%)** | 88 (98.9) | 87 (98.9) | 44 (97.8) | 43 (100) | 44 (100) | 44 (97.8) |
| Disease progression | 70 (78.7) | 50 (56.8) | 38 (84.4) | 30 (69.8) | 32 (72.7) | 20 (44.4) |
| Adverse event | 14 (15.7) | 24 (27.3) | 4 (8.9) | 8 (18.6) | 10 (22.7) | 16 (35.6) |
| Patient request | 1 (1.1) | 5 (5.7) | 1 (2.2) | 2 (4.7) | 0 | 3 (6.7) |
| Other | 3 (3.4) | 8 (9.1) | 1 (2.2) | 3 (7.0) | 2 (4.5) | 5 (11.1) |

\*Relative dose intensity is defined as the ratio of the actual dose intensity (the cumulative dose divided by the number of weeks on study) to the planned dose intensity.

**SUPPLEMENTARY FIGURE S1. CONSORT diagram**

